Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the HM Treasury:
To ask the Chancellor of the Exchequer, what assessment her Department has made of the potential impact of alcohol duty increases on 1 February 2025 on revenue from alcohol duty receipts.
Answered by Dan Tomlinson - Exchequer Secretary (HM Treasury)
Alcohol duty receipts for the period March 2025 to October 2025, following the February 2025 rate increase, totalled £7.8 billion, down 4.5% from the same period in 2024 when receipts totalled £8.1 billion. This is driven by an underlying fall in alcohol consumption. Likely factors causing this decline, as identified in the Office for Budget Responsibility's Economic and Fiscal Outlook report published in November 2025, are a growing trend of alcohol moderation and a response to higher prices, as well as a potential impact from demographic changes. You can find the report here: https://obr.uk/economic-and-fiscal-outlooks/
New forecasts for alcohol duty have been produced for Autumn Budget 2025, as shared in the Office for Budget Responsibility's Economic and Fiscal Outlook.
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the HM Treasury:
To ask the Chancellor of the Exchequer, if she will revise forward-looking forecasts for revenue from alcohol duty.
Answered by Dan Tomlinson - Exchequer Secretary (HM Treasury)
Alcohol duty receipts for the period March 2025 to October 2025, following the February 2025 rate increase, totalled £7.8 billion, down 4.5% from the same period in 2024 when receipts totalled £8.1 billion. This is driven by an underlying fall in alcohol consumption. Likely factors causing this decline, as identified in the Office for Budget Responsibility's Economic and Fiscal Outlook report published in November 2025, are a growing trend of alcohol moderation and a response to higher prices, as well as a potential impact from demographic changes. You can find the report here: https://obr.uk/economic-and-fiscal-outlooks/
New forecasts for alcohol duty have been produced for Autumn Budget 2025, as shared in the Office for Budget Responsibility's Economic and Fiscal Outlook.
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the adequacy of the availability of ADHD medication.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department has made substantial progress in improving the availability of medicines for attention deficit hyperactivity disorder (ADHD), working closely with industry and key stakeholders to resolve previous supply challenges. Through intensive work with industry, NHS England and the Medicines and Healthcare products Regulatory Agency have resolved most of the previous shortages. All strengths of lisdexamfetamine, atomoxetine, both the capsules and the oral solution, guanfacine prolonged-release tablets, and methylphenidate prolonged-release tablets are now available.
There is a current supply issue with methylphenidate 30 milligram prolonged-release capsules, brand name Equasym XL, which is out of stock until late December. The Department has issued guidance to healthcare professionals with advice on how to manage patients until this shortage resolves.
We continue to work closely with suppliers to resolve the few remaining challenges and to strengthen resilience in the supply chain. This includes securing additional stocks, expediting deliveries, and expanding the United Kingdom supplier base to support future demand. In collaboration with NHS England’s ADHD taskforce and national data improvement plan, we are developing growth forecasts to improve demand planning and ensure a sustainable supply of ADHD medicines.
To support prescribers and dispensers, the Department maintains and regularly updates a list of currently available and unavailable ADHD products on the Specialist Pharmacy Service website, at the following link:
www.sps.nhs.uk/articles/prescribing-available-medicines-to-treat-adhd